Exclusive Summary

• Possesses dual US-FDA and PIC/S GMP certifications, providing exceptionally strong quality endorsements for rapid entry into highly regulated markets and fast-track registration in emerging markets.
• Targets the booming reproductive health sector with unyielding demand, as WHO reports 1 in 6 people globally experience infertility, driving explosive growth in ART/IVF cycles.
• Serves as the first-line standard of care for Luteal Phase Support (LPS) recommended by global guidelines, featuring a high manufacturing barrier for vaginal suppositories that ensures a less crowded competitive landscape.
• Perfectly timed to capture market share amidst global supply chain shortages of innovator brands, offering overseas partners a high-margin, reliable alternative under a flexible Distribution model.